Johnson & Johnson is beginning 2024 by making another bet on antibody-drug conjugates (ADCs) with the acquisition of Ambrx Biopharma, Inc., which the drug maker announced shortly before CEO Joaquin Duato spoke in a fireside chat at the J.P. Morgan Healthcare Conference.
J&J announced on 8 January that it will take over Ambrx for about $2bn in an all-cash merger
Key Takeaways
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?